津药药业：氯化钾注射液新增规格及通过一致性评价

Core Viewpoint - Tianyao Pharmaceutical (600488) announced the approval of its subsidiary Hubei Tianyao's potassium chloride injection by the National Medical Products Administration, which includes new specifications and passes the consistency evaluation of generic drug quality and efficacy [1][2]. Group 1 - The potassium chloride injection is classified as a Class A product under the National Medical Insurance (2023) and is used for the treatment and prevention of hypokalemia, particularly when oral potassium supplementation is not feasible [2].